Efficacy and steroid-sparing effect of benralizumab

Has it an advantage over its competitors?

Francesco Menzella, Mirella Biava, Diego Bagnasco, Carla Galeone, Anna Simonazzi, Patrizia Ruggiero, Nicola Facciolongo

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Severe refractory asthma is characterized by a higher risk of asthma-related symptoms, morbidities, and exacerbations. This disease also determines much greater healthcare costs and deterioration in health-related quality of life (HR-QoL). Another concern, which is currently much discussed, is the high percentage of patients needing regular use of oral corticosteroids (OCS), which can lead to several systemic side effects. Airway eosinophilia is present in the majority of asthmatic patients, and elevated levels of blood and sputum eosinophils are associated with worse control of asthma. Regarding severe refractory eosinophilic asthma, interleukin-5 (IL-5) plays a fundamental role in the inflammatory response, due to the profound effect on eosinophils biology. The advent of the biological therapies provided an effective strategy, even if the increased number of molecules with different targets raised the challenge of choosing the right therapy and avoid overlapping. When considering severe refractory eosinophilic asthma and anti-IL-5 treatments, it is not easy to define which drug to choose between mepolizumab, reslizumab, and benralizumab. In this article, we carried out an indirect comparison among literature data, especially between OCS reduction studies (ZONDA-SIRIUS) and pivotal studies (SIROCCO-MENSA), evaluating whether the clinical efficacy and the steroid-sparing effect of benralizumab may represent an advantage over other compounds. This data could help the clinician in the decision process of treatment choice, within the different available therapeutic options for eosinophilic refractory severe asthma.

Original languageEnglish
Article number212580
JournalDrugs in Context
Volume8
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Asthma
Steroids
Interleukin-5
Eosinophils
Adrenal Cortex Hormones
Biological Therapy
Eosinophilia
Therapeutics
Sputum
Health Care Costs
benralizumab
Quality of Life
Morbidity
Pharmaceutical Preparations

Keywords

  • Comparison
  • Eosinophils
  • Oral corticosteroids
  • Randomized clinical trials
  • Side effects
  • Steroid-sparing effect

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Efficacy and steroid-sparing effect of benralizumab : Has it an advantage over its competitors? / Menzella, Francesco; Biava, Mirella; Bagnasco, Diego; Galeone, Carla; Simonazzi, Anna; Ruggiero, Patrizia; Facciolongo, Nicola.

In: Drugs in Context, Vol. 8, 212580, 01.01.2019.

Research output: Contribution to journalReview article

Menzella, Francesco ; Biava, Mirella ; Bagnasco, Diego ; Galeone, Carla ; Simonazzi, Anna ; Ruggiero, Patrizia ; Facciolongo, Nicola. / Efficacy and steroid-sparing effect of benralizumab : Has it an advantage over its competitors?. In: Drugs in Context. 2019 ; Vol. 8.
@article{b62a5fcb92914da2b0022c83e16a6848,
title = "Efficacy and steroid-sparing effect of benralizumab: Has it an advantage over its competitors?",
abstract = "Severe refractory asthma is characterized by a higher risk of asthma-related symptoms, morbidities, and exacerbations. This disease also determines much greater healthcare costs and deterioration in health-related quality of life (HR-QoL). Another concern, which is currently much discussed, is the high percentage of patients needing regular use of oral corticosteroids (OCS), which can lead to several systemic side effects. Airway eosinophilia is present in the majority of asthmatic patients, and elevated levels of blood and sputum eosinophils are associated with worse control of asthma. Regarding severe refractory eosinophilic asthma, interleukin-5 (IL-5) plays a fundamental role in the inflammatory response, due to the profound effect on eosinophils biology. The advent of the biological therapies provided an effective strategy, even if the increased number of molecules with different targets raised the challenge of choosing the right therapy and avoid overlapping. When considering severe refractory eosinophilic asthma and anti-IL-5 treatments, it is not easy to define which drug to choose between mepolizumab, reslizumab, and benralizumab. In this article, we carried out an indirect comparison among literature data, especially between OCS reduction studies (ZONDA-SIRIUS) and pivotal studies (SIROCCO-MENSA), evaluating whether the clinical efficacy and the steroid-sparing effect of benralizumab may represent an advantage over other compounds. This data could help the clinician in the decision process of treatment choice, within the different available therapeutic options for eosinophilic refractory severe asthma.",
keywords = "Comparison, Eosinophils, Oral corticosteroids, Randomized clinical trials, Side effects, Steroid-sparing effect",
author = "Francesco Menzella and Mirella Biava and Diego Bagnasco and Carla Galeone and Anna Simonazzi and Patrizia Ruggiero and Nicola Facciolongo",
year = "2019",
month = "1",
day = "1",
doi = "10.7573/dic.212580",
language = "English",
volume = "8",
journal = "Drugs in Context",
issn = "1745-1981",
publisher = "JUST Medical Media Limited",

}

TY - JOUR

T1 - Efficacy and steroid-sparing effect of benralizumab

T2 - Has it an advantage over its competitors?

AU - Menzella, Francesco

AU - Biava, Mirella

AU - Bagnasco, Diego

AU - Galeone, Carla

AU - Simonazzi, Anna

AU - Ruggiero, Patrizia

AU - Facciolongo, Nicola

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Severe refractory asthma is characterized by a higher risk of asthma-related symptoms, morbidities, and exacerbations. This disease also determines much greater healthcare costs and deterioration in health-related quality of life (HR-QoL). Another concern, which is currently much discussed, is the high percentage of patients needing regular use of oral corticosteroids (OCS), which can lead to several systemic side effects. Airway eosinophilia is present in the majority of asthmatic patients, and elevated levels of blood and sputum eosinophils are associated with worse control of asthma. Regarding severe refractory eosinophilic asthma, interleukin-5 (IL-5) plays a fundamental role in the inflammatory response, due to the profound effect on eosinophils biology. The advent of the biological therapies provided an effective strategy, even if the increased number of molecules with different targets raised the challenge of choosing the right therapy and avoid overlapping. When considering severe refractory eosinophilic asthma and anti-IL-5 treatments, it is not easy to define which drug to choose between mepolizumab, reslizumab, and benralizumab. In this article, we carried out an indirect comparison among literature data, especially between OCS reduction studies (ZONDA-SIRIUS) and pivotal studies (SIROCCO-MENSA), evaluating whether the clinical efficacy and the steroid-sparing effect of benralizumab may represent an advantage over other compounds. This data could help the clinician in the decision process of treatment choice, within the different available therapeutic options for eosinophilic refractory severe asthma.

AB - Severe refractory asthma is characterized by a higher risk of asthma-related symptoms, morbidities, and exacerbations. This disease also determines much greater healthcare costs and deterioration in health-related quality of life (HR-QoL). Another concern, which is currently much discussed, is the high percentage of patients needing regular use of oral corticosteroids (OCS), which can lead to several systemic side effects. Airway eosinophilia is present in the majority of asthmatic patients, and elevated levels of blood and sputum eosinophils are associated with worse control of asthma. Regarding severe refractory eosinophilic asthma, interleukin-5 (IL-5) plays a fundamental role in the inflammatory response, due to the profound effect on eosinophils biology. The advent of the biological therapies provided an effective strategy, even if the increased number of molecules with different targets raised the challenge of choosing the right therapy and avoid overlapping. When considering severe refractory eosinophilic asthma and anti-IL-5 treatments, it is not easy to define which drug to choose between mepolizumab, reslizumab, and benralizumab. In this article, we carried out an indirect comparison among literature data, especially between OCS reduction studies (ZONDA-SIRIUS) and pivotal studies (SIROCCO-MENSA), evaluating whether the clinical efficacy and the steroid-sparing effect of benralizumab may represent an advantage over other compounds. This data could help the clinician in the decision process of treatment choice, within the different available therapeutic options for eosinophilic refractory severe asthma.

KW - Comparison

KW - Eosinophils

KW - Oral corticosteroids

KW - Randomized clinical trials

KW - Side effects

KW - Steroid-sparing effect

UR - http://www.scopus.com/inward/record.url?scp=85069716531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069716531&partnerID=8YFLogxK

U2 - 10.7573/dic.212580

DO - 10.7573/dic.212580

M3 - Review article

VL - 8

JO - Drugs in Context

JF - Drugs in Context

SN - 1745-1981

M1 - 212580

ER -